Neurobo Pharmaceuticals Inc Company Overview
About Neurobo Pharmaceuticals Inc
Neurobo Pharmaceuticals (NASDAQ:NRBO) focuses on the development and commercialization of innovative therapies targeting neurodegenerative and rare diseases. Operating primarily on the NASDAQ exchange, Neurobo is advancing a promising pipeline of products aimed at treating disorders like Alzheimer's and diabetic neuropathic pain. The company explores drug candidates that address unmet medical needs, enhancing patient care and quality of life. Neurobo is engaged in strategic partnerships and collaborations, which bolster its research and development efforts. The company is committed to leveraging cutting-edge science to transform treatments and aims to deliver effective therapies in the shortest feasible timeline. With a patient-centric approach, Neurobo is dedicated to pioneering medical breakthroughs.
Snapshot
Operations
Produtos e/ou serviços de Neurobo Pharmaceuticals Inc
- ANA001: A clinical-stage proprietary oral niclosamide formulation aimed at treating COVID-19 and IRDS through its antiviral and anti-inflammatory properties.
- NB-01: Designed to offer therapeutic benefits for pain arising from diabetic neuropathy through a proprietary mixture of traditional Chinese medicine extracts.
- NB-02: Focused on revitalizing nerve and muscle health, this drug targets peripheral nerves affected by diabetes through the modulation of specific enzymes.
- KLS-13019: Targets chronic pain and inflammation, exploring potential therapeutic approaches with novel cannabinoid technology for neurodegenerative conditions.
- NB-04: A preclinical candidate in development focusing on obesity and the potential to regulate energy balance and metabolic disorders.
- Partnerships: Collaborative agreements with institutions and firms engaged in developing complementary therapeutics or advancing existing projects through innovative research.
equipe executiva do Neurobo Pharmaceuticals Inc
- Mr. Hyung-Heon KimCEO, President & Director
- Mr. Marshall H. WoodworthChief Financial Officer
- Dr. Mi-Kyung KimChief Scientific Officer
- Mr. Robert HomolkaSenior Vice President of Clinical Operations